Publications by authors named "Pascal Lenain"

Claim this Profile
C
Concordance between Tympanic and Enteral Temperature for Early Fever Detection in Hematologic Intensive Care Unit Patients: A Prospective Study.
Florian Bouclet, Juliette Pénichoux, Sorina-Dana Mihailescu, Stéphanie Seris, Lucie Burel, Pascal Lenain

Acta Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study.
Arthur Bobin, Salomon Manier, Joe De Keizer, Jaydeep K Srimani, Cyrille Hulin, Pascal Lenain

Haematologica· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study.
Juliette Pénichoux, Hélène Lanic, Caroline Thill, Anne-Lise Ménard, Vincent Camus, Pascal Lenain

Ann Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Alexis Talbot, Arthur Bobin, Léa Tabone, Jérôme Lambert, Catherine Boccaccio, Pascal Lenain

Haematologica· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study.
Juliette Pénichoux, Hélène Lanic, Caroline Thill, Anne-Lise Ménard, Vincent Camus, Pascal Lenain

Ann Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Laurent Garderet, Frederique Kuhnowski, Benoit Berge, Murielle Roussel, Laure Devlamynck, Pascal Lenain

Br J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock.
Antoine Herault, Emilie Lévêque, Simon Draye-Carbonnier, Pierre Decazes, Alexandra Zduniak, Pascal Lenain

Clin Nutr ESPEN· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Anais Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, Titouan Cazaubiel, Marie-Lorraine Chretien, Pascal Lenain

Haematologica· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, Agnès Guerci-Bresler, Martine Escoffre-Barbe, Pascal Lenain

Br J Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Stéphanie Dulucq, Franck E Nicolini, Delphine Rea, Pascale Cony-Makhoul, Aude Charbonnier, Pascal Lenain

Haematologica· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
Alexandra Zduniak, Emilie Lévêque, Anne Perdrix, Pascaline Etancelin, Anne-Lise Ménard, Pascal Lenain

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma.
Juliette Pénichoux, Julien Rio, Leila Kammoun, Thomas Vermeulin, Louis-Ferdinand Pepin, Pascal Lenain

Eur J Haematol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Pascal Lenain

Blood· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Arthur Bobin, Maéva Kyheng, Stéphanie Guidez, Cécile Gruchet-Merouze, Valentine Richez, Pascal Lenain

Leukemia· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
Laure Vincent, Luuk Gras, Patrice Ceballos, Jürgen Finke, Jakob Passweg, Pascal Lenain

Bone Marrow Transplant· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.
Alexis Caulier, Murielle Roussel, Pierre Morel, Naelle Lombion, Benoît Branco, Pascal Lenain

Blood· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relevance of lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience.
Juliette Pénichoux, Sydney Dubois, Daphné Krzisch, Anne-Lise Menard, Hélène Lanic, Pascal Lenain

Leuk Lymphoma· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Francois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, Agnès-Paule Guerci-Bresler, Frédéric Maloisel, Pascal Lenain

Leukemia· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell lymphoma patients: A real-life study.
Alexandra Zduniak, Sorina-Dana Mihailescu, Justine Lequesne, Pascal Lenain, Nathalie Contentin

Eur J Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.
Vincent Camus, Mathieu Viennot, Justine Lequesne, Pierre-Julien Viailly, Elodie Bohers, Pascal Lenain

Haematologica· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma.
Zoé Van de Wyngaert, Virginie Nerich, Guillemette Fouquet, Marie-Lorraine Chrétien, Denis Caillot, Pascal Lenain

Bone Marrow Transplant· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Franck Emmanuel Nicolini, Stéphanie Dulucq, Lisa Boureau, Pascale Cony-Makhoul, Aude Charbonnier, Pascal Lenain

Clin Cancer Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Xavier Leleu, Guillemette Fouquet, Valentine Richez, Stéphanie Guidez, Alain Duhamel, Pascal Lenain

Clin Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Pascal Lenain

Lancet· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21-year-old patient: A case report and review.
Vincent Camus, Sydney Dubois, Pierre-Alain Thiébaut, Stéphane Lepretre, Pascal Lenain

Clin Case Rep· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis